» Articles » PMID: 22335496

Targeting RSV with Vaccines and Small Molecule Drugs

Overview
Date 2012 Feb 17
PMID 22335496
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Respiratory syncytial virus (RSV) is the most significant cause of pediatric respiratory infections. Palivizumab (Synagis®), a humanized monoclonal antibody, has been used successfully for a number of years to prevent severe RSV disease in at-risk infants. However, despite intense efforts, there is no approved vaccine or small molecule drug for RSV. As an enveloped virus, RSV must fuse its envelope with the host cell membrane, which is accomplished through the actions of the fusion (F) glycoprotein, with attachment help from the G glycoprotein. Because of their integral role in initiation of infection and their accessibility outside the lipid bilayer, these proteins have been popular targets in the discovery and development of antiviral compounds and vaccines against RSV. This review examines advances in the development of antiviral compounds and vaccine candidates.

Citing Articles

Potentiality of bioactive compounds as inhibitor of M protein and F protein function of human respiratory syncytial virus.

Mitra D, Paul M, Thatoi H, Mohapatra P In Silico Pharmacol. 2023; 12(1):5.

PMID: 38148755 PMC: 10749291. DOI: 10.1007/s40203-023-00178-w.


Synthesis and evaluation of 3-alkynyl-5-aryl-7-aza-indoles as broad-spectrum antiviral agents.

Martinez-Gualda B, Graus M, Camps A, Vanhulle E, Saul S, Azari S Front Chem. 2022; 10:1058229.

PMID: 36385995 PMC: 9643853. DOI: 10.3389/fchem.2022.1058229.


Respiratory syncytial virus entry and how to block it.

Battles M, McLellan J Nat Rev Microbiol. 2019; 17(4):233-245.

PMID: 30723301 PMC: 7096974. DOI: 10.1038/s41579-019-0149-x.


T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Monette A, Mouland A Int Rev Cell Mol Biol. 2019; 342:175-263.

PMID: 30635091 PMC: 7104940. DOI: 10.1016/bs.ircmb.2018.07.006.


Five Residues in the Apical Loop of the Respiratory Syncytial Virus Fusion Protein F Subunit Are Critical for Its Fusion Activity.

Hicks S, Chaiwatpongsakorn S, Costello H, McLellan J, Ray W, Peeples M J Virol. 2018; 92(15).

PMID: 29743373 PMC: 6052300. DOI: 10.1128/JVI.00621-18.


References
1.
Schickli J, Dubovsky F, Tang R . Challenges in developing a pediatric RSV vaccine. Hum Vaccin. 2009; 5(9):582-91. DOI: 10.4161/hv.9131. View

2.
Haynes L, Jones L, Barskey A, Anderson L, Tripp R . Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J Virol. 2003; 77(18):9831-44. PMC: 224581. DOI: 10.1128/jvi.77.18.9831-9844.2003. View

3.
Crowe Jr J, Bui P, Siber G, Elkins W, Chanock R, Murphy B . Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine. 1995; 13(9):847-55. DOI: 10.1016/0264-410x(94)00074-w. View

4.
Bonfanti J, Doublet F, Fortin J, Lacrampe J, Guillemont J, Muller P . Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship. J Med Chem. 2007; 50(19):4572-84. DOI: 10.1021/jm070143x. View

5.
Wyde P, OHara B, Ding W, Mitsner B, Gilbert B . CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats. Antiviral Res. 1998; 38(1):31-42. DOI: 10.1016/s0166-3542(98)00002-3. View